Transgene (TNGP) Stock Overview
A biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
TNGP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Transgene SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.01 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 0.73 |
| 1 Month Change | 0% |
| 3 Month Change | -12.62% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -48.26% |
| Change since IPO | -89.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| TNGP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 2.4% |
| 1Y | n/a | -5.5% | 19.0% |
Return vs Industry: Insufficient data to determine how TNGP performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how TNGP performed against the UK Market.
Price Volatility
| TNGP volatility | |
|---|---|
| TNGP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: TNGP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TNGP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 141 | Alessandro Riva | www.transgene.com |
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
Transgene SA Fundamentals Summary
| TNGP fundamental statistics | |
|---|---|
| Market cap | €139.91m |
| Earnings (TTM) | -€22.33m |
| Revenue (TTM) | €7.90m |
Is TNGP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNGP income statement (TTM) | |
|---|---|
| Revenue | €7.90m |
| Cost of Revenue | €29.59m |
| Gross Profit | -€21.69m |
| Other Expenses | €640.00k |
| Earnings | -€22.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 24, 2024
| Earnings per share (EPS) | -0.17 |
| Gross Margin | -274.53% |
| Net Profit Margin | -282.63% |
| Debt/Equity Ratio | 102.7% |
How did TNGP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/14 20:07 |
| End of Day Share Price | 2024/06/18 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Transgene SA is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arsene Guekam | CIC Market Solutions (ESN) |
| Michael Thomas Cooper | Edison Investment Research |
| Martial Descoutures | ODDO BHF Corporate & Markets |